Drug intelligence / Profile preview

Momordica saponin I

Development stage: Unknown
Lead developer: Adjuvax
Modality: Small Molecules
Administration: Intramuscular, Subcutaneous

Overview

Momordica saponin I is a natural product saponin adjuvant developed by Adjuvax. Extracted from the seeds of *Momordica cochinchinensis*, it is utilized as an immunostimulant in vaccine formulations to enhance the immune response to antigens. Saponin-based adjuvants are recognized for their ability to stimulate both cellular (Th1) and humoral (Th2) immunity, often by promoting antigen presentation and activating innate immune pathways. Adjuvax offers Momordica saponin I commercially for research and development purposes, and it is part of a broader portfolio of saponin-based adjuvants intended for both human and veterinary vaccine applications.

Other names: Momordica saponin IMS-I

Beyond the preview

Go deeper on Momordica saponin I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Momordica saponin I.

Explore the full profile